Next review: 2024 Commercial arrangements See NICE technology appraisal guidance 375 for details. Some of the treatments recommended in this appraisal for moderate rheumatoid arthritis are also recommended for severe rheumatoid arthritis. The recommendations also apply to biosimilar products of the technologies that have a marketing authorisation allowing the use of the biosimilar for the same indication. Evidence-based recommendations on adalimumab, etanercept, infliximab and abatacept for adults with moderate rheumatoid arthritis who have tried conventional DMARDs but they have not worked.
0 Comments
Leave a Reply. |